BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33893740)

  • 1. Predictors of early recurrence following neoadjuvant chemotherapy and surgical resection for localized pancreatic adenocarcinoma.
    Narayanan S; AlMasri S; Zenati M; Nassour I; Chopra A; Rieser C; Smith K; Oyefusi V; Daum T; Bahary N; Bartlett D; Lee K; Zureikat A; Paniccia A
    J Surg Oncol; 2021 Sep; 124(3):308-316. PubMed ID: 33893740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy.
    Roland CL; Katz MH; Tzeng CW; Lin H; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Vauthey JN; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S1221-8. PubMed ID: 26350371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resection of pancreatic ductal adenocarcinoma with synchronous distant metastasis: is it worthwhile?
    Buc E; Orry D; Antomarchi O; Gagnière J; Da Ines D; Pezet D
    World J Surg Oncol; 2014 Nov; 12():347. PubMed ID: 25407113
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Timing But Not Patterns of Recurrence Is Different Between Node-negative and Node-positive Resected Pancreatic Cancer.
    Honselmann KC; Pergolini I; Castillo CF; Deshpande V; Ting D; Taylor MS; Bolm L; Qadan M; Wellner U; Sandini M; Bausch D; Warshaw AL; Lillemoe KD; Keck T; Ferrone CR
    Ann Surg; 2020 Aug; 272(2):357-365. PubMed ID: 32675550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of preoperative prognostic factors in patients with resectable pancreatic ductal adenocarcinoma.
    Izumo W; Higuchi R; Furukawa T; Yazawa T; Uemura S; Shiihara M; Yamamoto M
    Scand J Gastroenterol; 2019 Jun; 54(6):780-786. PubMed ID: 31180790
    [No Abstract]   [Full Text] [Related]  

  • 7. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
    Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
    Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after curative intent surgical resection.
    Kim NH; Kim HJ
    Hepatobiliary Pancreat Dis Int; 2018 Oct; 17(5):450-455. PubMed ID: 30237091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A preoperative risk model for early recurrence after radical resection may facilitate initial treatment decisions concerning the use of neoadjuvant therapy for patients with pancreatic ductal adenocarcinoma.
    Guo SW; Shen J; Gao JH; Shi XH; Gao SZ; Wang H; Li B; Yuan WL; Lin L; Jin G
    Surgery; 2020 Dec; 168(6):1003-1014. PubMed ID: 32321665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
    Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
    J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Microscopic tumor mapping of post-neoadjuvant therapy pancreatic cancer specimens to predict post-surgical recurrence: A prospective cohort study.
    Park Y; Han YB; Kim J; Kang M; Lee B; Ahn ES; Han S; Kim H; Na HY; Han HS; Yoon YS
    Pancreatology; 2024 Jun; 24(4):562-571. PubMed ID: 38556428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Surgical therapy of pancreatic cancer - 5 years survival].
    Loveček M; Skalický P; Klos D; Neoral Č; Ehrmann J; Zapletalová J; Švébišová H; Yogeswara T; Ghothim M; Vrba R; Havlík R
    Rozhl Chir; 2015 Nov; 94(11):470-6. PubMed ID: 26766155
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
    Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
    Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Loco-recurrence after resection for ductal adenocarcinoma of the pancreas: predictors and implications for adjuvant chemoradiotherapy.
    Zhang Y; Frampton AE; Kyriakides C; Bong JJ; Habib N; Ahmad R; Jiao LR
    J Cancer Res Clin Oncol; 2012 Jun; 138(6):1063-71. PubMed ID: 22392075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of completion pancreatectomy for recurrence of adenocarcinoma in the remnant pancreas.
    Nakayama Y; Sugimoto M; Gotohda N; Konishi M; Takahashi S
    J Surg Res; 2018 Jan; 221():15-23. PubMed ID: 29229121
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The canary in the coal mine: the growth of patient-derived tumorgrafts in mice predicts clinical recurrence after surgical resection of pancreatic ductal adenocarcinoma.
    Thomas RM; Truty MJ; Kim M; Kang Y; Zhang R; Chatterjee D; Katz MH; Fleming JB
    Ann Surg Oncol; 2015; 22(6):1884-92. PubMed ID: 25404477
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Perineural Invasion of Pancreatic Ductal Adenocarcinoma is Associated with Early Recurrence after Neoadjuvant Therapy Followed by Resection.
    Cha DE; Yu AT; Khajoueinejad N; Gleeson E; Shaltiel T; Berger Y; Macfie R; Golas BJ; Sarpel U; Labow DM; Hiotis S; Cohen NA
    World J Surg; 2023 Jul; 47(7):1801-1808. PubMed ID: 37014430
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of neoadjuvant therapy on postoperative outcomes after pancreaticoduodenectomy.
    Cools KS; Sanoff HK; Kim HJ; Yeh JJ; Stitzenberg KB
    J Surg Oncol; 2018 Sep; 118(3):455-462. PubMed ID: 30114330
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian Approach to Understand the Association Between Treatment Down-staging and Survival for Patients With Pancreatic Adenocarcinoma.
    da Costa WL; Tran Cao HS; Gu X; Massarweh NN
    Ann Surg; 2022 Mar; 275(3):415-421. PubMed ID: 35120060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.